Thrombopoietin generally refers to recombinant human thrombopoietin injection, and the main function of this drug is to stimulate the growth and differentiation of megakaryocytes in the body, and increase the number of platelets in the patient’s body. At the same time, clinical research has found that the drug has a good auxiliary therapeutic effect on idiopathic thrombocytopenic purpura.
The main components of recombinant human thrombopoietin injection are recombinant human thrombopoietin, human blood albumin, etc. After entering the human body, it can stimulate the megakaryocytes in the human body, accelerate the growth and differentiation of megakaryocytes, so as to improve the number of platelets in the patient’s body.
Thrombopoietin is mainly applied to patients suffering from malignant tumors, whose platelet count is significantly reduced after radiotherapy and chemotherapy. Clinics generally recommend patients to choose the appropriate dose for treatment within 6 to 24 hours after the operation under the guidance of doctors based on the standard of 300U/kg body weight per day.
However, it is forbidden for patients who are allergic to the components of the drug, have serious cardiovascular and cerebrovascular diseases, suffer from other blood hypercoagulable diseases, combined with serious infections, and have recently occurred thrombophilia.
In conclusion, recombinant human thrombopoietin injection has important clinical significance, and it is recommended that patients with the above mentioned reduction in platelet count use the drug in strict compliance with the doctor’s prescription.